title: [Anaphylaxis and anaphylactic shock].
abstract: Term anaphylaxis means an immediate hypersensitivity reaction mediated by IgE that produces a clinical syndrome with systemic affection of variable severity. Its prevalence varies according to the habits of each region and of the studied population from 3.2 to 7.6 cases per 100,000 inhabitants per year. Anaphylaxis secondary to the food ingestion accounts for 30-50% of the cases. Some risk factors have been defined, among them the most important are asthma, food allergy and previous reactions to the same food. Biphasic anaphylactic reactions are those presenting a recurrence of anaphylactic symptoms, after the initial remission of them. Success of treatment is based on the early recognition of signs and symptoms and the instauration of treatment with adrenaline.
authors.affiliation: Hospital Infantil de México Federico Gómez.
authors.forename: M J E
authors.initials: MJ
authors.lastname: Mendoza Magaña
authors.forename: M A
authors.initials: MA
authors.lastname: Vargas Rosasm
authors.forename: J E
authors.initials: JE
authors.lastname: Guillén Escalón
authors.forename: A M
authors.initials: AM
authors.lastname: Moncada Alcon
authors.forename: Blanca Estela
authors.initials: BE
authors.lastname: del Río Navarro
authors.forename: Juan José Luis
authors.initials: JJ
authors.lastname: Sienra Monge
mesh_terms: D000485:Allergens / Q000009:adverse effects; D000707:Anaphylaxis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology; D001285:Atropine / Q000627:therapeutic use; D002630:Chemotactic Factors / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000627:therapeutic use; D005440:Fluid Therapy; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006636:Histamine Release; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D008407:Mast Cells / Q000378:metabolism; D008775:Methylprednisolone / Q000627:therapeutic use; D015995:Prevalence; D015230:Prostaglandin D2 / Q000378:metabolism; D012307:Risk Factors; D019851:Thrombophilia / Q000209:etiology; D053802:Tryptases / Q000378:metabolism; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
chemical_list: D000485:Allergens; D002630:Chemotactic Factors; D016207:Cytokines; D006634:Histamine H1 Antagonists; D014662:Vasoconstrictor Agents; D007073:Immunoglobulin E; D001285:Atropine; D053802:Tryptases; D015230:Prostaglandin D2; D008775:Methylprednisolone; D004837:Epinephrine